PPACK and Bivalirudin nanoparticles enable simultaneous imaging and potent inhibition of acute clotting

In recent work, a thrombin-inhibiting perfluorocarbon nanoparticle (PFC NP), functionalized by the direct thrombin inhibitor, PPACK (Phe(D)-Pro-Arg-Chloromethylketone), was presented as a prototype for novel class of targeted antithrombotic. Figure 1 [figure omitted; refer to PDF] Figure 2 [figure o...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiovascular magnetic resonance Vol. 14; no. S1; p. O41
Main Authors Myerson, Jacob W, Allen, John S, Williams, Todd A, He, Li, Tollefsen, Douglas M, Lanza, Gregory, Caruthers, Shelton D, Wickline, Samuel A
Format Journal Article
LanguageEnglish
Published New York BioMed Central 01.02.2012
BioMed Central Ltd
Elsevier
Subjects
Anticoagulants
Drug therapy
Oral Presentation
Perfluorocarbons
Veins & arteries
Online AccessGet full text

Cover

More Information
Summary:In recent work, a thrombin-inhibiting perfluorocarbon nanoparticle (PFC NP), functionalized by the direct thrombin inhibitor, PPACK (Phe(D)-Pro-Arg-Chloromethylketone), was presented as a prototype for novel class of targeted antithrombotic. Figure 1 [figure omitted; refer to PDF] Figure 2 [figure omitted; refer to PDF] Conclusions Anticoagulant PFC NPs were designed as new antithrombotics with intrinsic magnetic resonance contrast, concentrated therapeutic impact conferred by a thrombin-specific particle surface, and well-defined pharmacokinetics controlled by the particle itself.
ISSN:1532-429X
1097-6647
1532-429X
DOI:10.1186/1532-429X-14-S1-O41